November 2, 2017
Takeda CEO Christophe Weber Takeda Pharmaceutical enjoyed solid profits on a 3.6% rise in group sales in April-September, buoyed by strong performances from Entyvio (vedolizumab) globally and Takecab (vonoprazan) in Japan, prompting the company to up its full-year guidance through...read more